Skip Navigation

U.S. Department of Health & Human ServicesLink to www.hhs.gov
OMH Home

En Español
The Office of Minority Health (Phone: 1-800-444-6472)
About OMH
Our Services
Campaigns/Initiatives
Press Releases
Calendar
Employment
Publications
Federal Clearinghouses
Research
OPHS Home
Image of a person asking a questionNeed Help?
Contact Us

HIV/AIDS Observance Days Icon
Click for more information

AIDS.gov web site logo
AIDS.gov for Federal HIV/AIDS Information
Join Our Mailing ListJoin Our Mailing List
Click to sign up


OMH Content

Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Program (U19)

The purpose of IPCAVD program is to support the more advanced stages of vaccine research and development including: advanced stage preclinical research, such as vaccine optimization studies; Good Laboratory Practice (GLP) preclinical toxicology and safety studies; Good Manufacturing Practice vaccine production; pre-Investigational New Drug (IND) and IND submission; and clinical testing.

Eligible Applicants:
State governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Native American tribal governments (Federally recognized)
Independent school districts
City or township governments
Private institutions of higher education
County governments
Public and State controlled institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities

Description:

  • The purpose of IPCAVD program is to support the more advanced stages of vaccine research and development including: advanced stage preclinical research, such as vaccine optimization studies; Good Laboratory Practice (GLP) preclinical toxicology and safety studies; Good Manufacturing Practice vaccine production; pre-Investigational New Drug (IND) and IND submission; and clinical testing. The manufacture of vaccine product and the initiation of human studies over the duration of the award must be a feasible and established goal.
  • In FY 2007 and FY 2008, NIAID expects to award a total of $4 million to support the IPCAVD Program. -NIAID anticipates making 1-2 awards per year.
  • This initiative will be funded using the multi-project Cooperative Agreement (U19) award mechanism.
  • Eligible organizations include for-profit organizations, non-profit organizations, public or private institutions such as universities, colleges, hospitals, and laboratories; units of State government, and units of local government, eligible agencies of the Federal government, foreign institutions, domestic institutions, and faith-based or community-based organizations.
  • Eligible Principal Investigators include any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs.
  • An Institution may submit only one application annually; however, applications may include investigators from more than one institution if such arrangements enhance the scientific strength of the proposed research program. In addition, a Principal Investigator may serve as a Project Leader in another multi-project application if there is no scientific overlap with the application submitted by the Principal Investigator.

To read the full announcement, please visit:
http://grants.nih.gov/grants/guide/pa-files/PAR-06-286.html



Content Last Modified: 3/31/2006 2:13:00 PM
OMH Home  |  HHS Home  |  USA.gov  |  Disclaimer  |  Privacy Policy  |  HHS FOIA  |  Accessibility  |  Site Map  |  Contact Us  |  File Formats

Office of Minority Health
Toll Free: 1-800-444-6472 / Fax: 301-251-2160
Email: info@omhrc.gov

Provide Feedback